1
|
Giriyappagoudar M, Vastrad B, Horakeri R, Vastrad C. Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis. Biomedicines 2023; 11:3109. [PMID: 38137330 PMCID: PMC10740779 DOI: 10.3390/biomedicines11123109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Revised: 10/31/2023] [Accepted: 11/02/2023] [Indexed: 12/24/2023] Open
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with reduced quality of life and earlier mortality, but its pathogenesis and key genes are still unclear. In this investigation, bioinformatics was used to deeply analyze the pathogenesis of IPF and related key genes, so as to investigate the potential molecular pathogenesis of IPF and provide guidance for clinical treatment. Next-generation sequencing dataset GSE213001 was obtained from Gene Expression Omnibus (GEO), and the differentially expressed genes (DEGs) were identified between IPF and normal control group. The DEGs between IPF and normal control group were screened with the DESeq2 package of R language. The Gene Ontology (GO) and REACTOME pathway enrichment analyses of the DEGs were performed. Using the g:Profiler, the function and pathway enrichment analyses of DEGs were performed. Then, a protein-protein interaction (PPI) network was constructed via the Integrated Interactions Database (IID) database. Cytoscape with Network Analyzer was used to identify the hub genes. miRNet and NetworkAnalyst databaseswereused to construct the targeted microRNAs (miRNAs), transcription factors (TFs), and small drug molecules. Finally, receiver operating characteristic (ROC) curve analysis was used to validate the hub genes. A total of 958 DEGs were screened out in this study, including 479 up regulated genes and 479 down regulated genes. Most of the DEGs were significantly enriched in response to stimulus, GPCR ligand binding, microtubule-based process, and defective GALNT3 causes HFTC. In combination with the results of the PPI network, miRNA-hub gene regulatory network and TF-hub gene regulatory network, hub genes including LRRK2, BMI1, EBP, MNDA, KBTBD7, KRT15, OTX1, TEKT4, SPAG8, and EFHC2 were selected. Cyclothiazide and rotigotinethe are predicted small drug molecules for IPF treatment. Our findings will contribute to identification of potential biomarkers and novel strategies for the treatment of IPF, and provide a novel strategy for clinical therapy.
Collapse
Affiliation(s)
- Muttanagouda Giriyappagoudar
- Department of Radiation Oncology, Karnataka Institute of Medical Sciences (KIMS), Hubballi 580022, Karnataka, India;
| | - Basavaraj Vastrad
- Department of Pharmaceutical Chemistry, K.L.E. Socitey’s College of Pharmacy, Gadag 582101, Karnataka, India;
| | - Rajeshwari Horakeri
- Department of Computer Science, Govt First Grade College, Hubballi 580032, Karnataka, India;
| | - Chanabasayya Vastrad
- Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karnataka, India
| |
Collapse
|
2
|
Lahmar Z, Ahmed E, Fort A, Vachier I, Bourdin A, Bergougnoux A. Hedgehog pathway and its inhibitors in chronic obstructive pulmonary disease (COPD). Pharmacol Ther 2022; 240:108295. [PMID: 36191777 DOI: 10.1016/j.pharmthera.2022.108295] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Revised: 08/22/2022] [Accepted: 09/28/2022] [Indexed: 11/05/2022]
Abstract
COPD affects millions of people and is now ranked as the third leading cause of death worldwide. This largely untreatable chronic airway disease results in irreversible destruction of lung architecture. The small lung hypothesis is now supported by epidemiological, physiological and clinical studies. Accordingly, the early and severe COPD phenotype carries the most dreadful prognosis and finds its roots during lung growth. Pathophysiological mechanisms remain poorly understood and implicate individual susceptibility (genetics), a large part of environmental factors (viral infections, tobacco consumption, air pollution) and the combined effects of those triggers on gene expression. Genetic susceptibility is most likely involved as the disease is severe and starts early in life. The latter observation led to the identification of Mendelian inheritance via disease-causing variants of SERPINA1 - known as the basis for alpha-1 anti-trypsin deficiency, and TERT. In the last two decades multiple genome wide association studies (GWAS) identified many single nucleotide polymorphisms (SNPs) associated with COPD. High significance SNPs are located in 4q31 near HHIP which encodes an evolutionarily highly conserved physiological inhibitor of the Hedgehog signaling pathway (HH). HHIP is critical to several in utero developmental lung processes. It is also implicated in homeostasis, injury response, epithelial-mesenchymal transition and tumor resistance to apoptosis. A few studies have reported decreased HHIP RNA and protein levels in human adult COPD lungs. HHIP+/- murine models led to emphysema. HH pathway inhibitors, such as vismodegib and sonidegib, are already validated in oncology, whereas other drugs have evidenced in vitro effects. Targeting the Hedgehog pathway could lead to a new therapeutic avenue in COPD. In this review, we focused on the early and severe COPD phenotype and the small lung hypothesis by exploring genetic susceptibility traits that are potentially treatable, thus summarizing promising therapeutics for the future.
Collapse
Affiliation(s)
- Z Lahmar
- Department of Respiratory Diseases, CHU de Montpellier, Montpellier, France
| | - E Ahmed
- Department of Respiratory Diseases, CHU de Montpellier, Montpellier, France; PhyMedExp, Univ Montpellier, Inserm U1046, CNRS UMR 9214, Montpellier, France
| | - A Fort
- PhyMedExp, Univ Montpellier, Inserm U1046, CNRS UMR 9214, Montpellier, France
| | - I Vachier
- Department of Respiratory Diseases, CHU de Montpellier, Montpellier, France; PhyMedExp, Univ Montpellier, Inserm U1046, CNRS UMR 9214, Montpellier, France
| | - A Bourdin
- Department of Respiratory Diseases, CHU de Montpellier, Montpellier, France; PhyMedExp, Univ Montpellier, Inserm U1046, CNRS UMR 9214, Montpellier, France
| | - A Bergougnoux
- PhyMedExp, Univ Montpellier, Inserm U1046, CNRS UMR 9214, Montpellier, France; Laboratoire de Génétique Moléculaire et de Cytogénomique, CHU de Montpellier, Montpellier, France.
| |
Collapse
|
3
|
Sauler M, McDonough JE, Adams TS, Kothapalli N, Barnthaler T, Werder RB, Schupp JC, Nouws J, Robertson MJ, Coarfa C, Yang T, Chioccioli M, Omote N, Cosme C, Poli S, Ayaub EA, Chu SG, Jensen KH, Gomez JL, Britto CJ, Raredon MSB, Niklason LE, Wilson AA, Timshel PN, Kaminski N, Rosas IO. Characterization of the COPD alveolar niche using single-cell RNA sequencing. Nat Commun 2022; 13:494. [PMID: 35078977 PMCID: PMC8789871 DOI: 10.1038/s41467-022-28062-9] [Citation(s) in RCA: 73] [Impact Index Per Article: 36.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Accepted: 12/14/2021] [Indexed: 12/16/2022] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide, however our understanding of cell specific mechanisms underlying COPD pathobiology remains incomplete. Here, we analyze single-cell RNA sequencing profiles of explanted lung tissue from subjects with advanced COPD or control lungs, and we validate findings using single-cell RNA sequencing of lungs from mice exposed to 10 months of cigarette smoke, RNA sequencing of isolated human alveolar epithelial cells, functional in vitro models, and in situ hybridization and immunostaining of human lung tissue samples. We identify a subpopulation of alveolar epithelial type II cells with transcriptional evidence for aberrant cellular metabolism and reduced cellular stress tolerance in COPD. Using transcriptomic network analyses, we predict capillary endothelial cells are inflamed in COPD, particularly through increased CXCL-motif chemokine signaling. Finally, we detect a high-metallothionein expressing macrophage subpopulation enriched in advanced COPD. Collectively, these findings highlight cell-specific mechanisms involved in the pathobiology of advanced COPD.
Collapse
Affiliation(s)
- Maor Sauler
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
| | - John E McDonough
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
| | - Taylor S Adams
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Neeharika Kothapalli
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Thomas Barnthaler
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
- Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria
| | - Rhiannon B Werder
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, 02118, USA
- The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, USA
- QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia
| | - Jonas C Schupp
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
- Department of Respiratory Medicine, Hannover Medical School and Biomedical Research in End-stage and Obstructive Lung Disease Hannover, German Lung Research Center (DZL), Hannover, Germany
| | - Jessica Nouws
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Matthew J Robertson
- Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Cristian Coarfa
- Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Tao Yang
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
- Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Maurizio Chioccioli
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Norihito Omote
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Carlos Cosme
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Sergio Poli
- Department of Internal Medicine, Mount Sinai Medical Center, Miami, FL, USA
| | - Ehab A Ayaub
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Sarah G Chu
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | | | - Jose L Gomez
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Clemente J Britto
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Micha Sam B Raredon
- Department of Biomedical Engineering, Yale University, New Haven, CT, USA
- Medical Scientist Training Program, Yale School of Medicine, New Haven, CT, USA
| | - Laura E Niklason
- Department of Biomedical Engineering, Yale University, New Haven, CT, USA
| | - Andrew A Wilson
- Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, 02118, USA
- The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, USA
| | | | - Naftali Kaminski
- Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Ivan O Rosas
- Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
4
|
Li Y, Zhang L, Polverino F, Guo F, Hao Y, Lao T, Xu S, Li L, Pham B, Owen CA, Zhou X. Hedgehog interacting protein (HHIP) represses airway remodeling and metabolic reprogramming in COPD-derived airway smooth muscle cells. Sci Rep 2021; 11:9074. [PMID: 33907231 PMCID: PMC8079715 DOI: 10.1038/s41598-021-88434-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Accepted: 04/07/2021] [Indexed: 02/05/2023] Open
Abstract
Although HHIP locus has been consistently associated with the susceptibility to COPD including airway remodeling and emphysema in genome-wide association studies, the molecular mechanism underlying this genetic association remains incompletely understood. By utilizing Hhip+/- mice and primary human airway smooth muscle cells (ASMCs), here we aim to determine whether HHIP haploinsufficiency increases airway smooth muscle mass by reprogramming glucose metabolism, thus contributing to airway remodeling in COPD pathogenesis. The mRNA levels of HHIP were compared in normal and COPD-derived ASMCs. Mitochondrial oxygen consumption rate and lactate levels in the medium were measured in COPD-derived ASMCs with or without HHIP overexpression as readouts of glucose oxidative phosphorylation and aerobic glycolysis rates. The proliferation rate was measured in healthy and COPD-derived ASMCs treated with or without 2-DG. Smooth muscle mass around airways was measured by immunofluorescence staining for α-smooth muscle actin (α-SMA) in lung sections from Hhip+/- mice and their wild type littermates, Hhip+/+ mice. Airway remodeling was assessed in Hhip+/- and Hhip+/- mice exposed to 6 months of cigarette smoke. Our results show HHIP inhibited aerobic glycolysis and represses cell proliferation in COPD-derived ASMCs. Notably, knockdown of HHIP in normal ASMCs increased PKM2 activity. Importantly, Hhip+/- mice demonstrated increased airway remodeling and increased intensity of α-SMA staining around airways compared to Hhip+/+ mice. In conclusion, our findings suggest that HHIP represses aerobic glycolysis and ASMCs hyperplasia, which may contribute to the increased airway remodeling in Hhip+/- mice.
Collapse
Affiliation(s)
- Yan Li
- School of Medicine, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong Province, China.
- Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
- Center for Reproductive Medicine, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong Province, China.
| | - Li Zhang
- Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
- Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China
| | - Francesca Polverino
- Asthma and Airway Disease Research Center, University of Arizona, Medicine, Tucson, AZ, 85724, USA
| | - Feng Guo
- Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
| | - Yuan Hao
- Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
| | - Taotao Lao
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, 02129, USA
| | - Shuang Xu
- Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
| | - Lijia Li
- Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
| | - Betty Pham
- Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
| | - Caroline A Owen
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
| | - Xiaobo Zhou
- Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
| |
Collapse
|
5
|
Ortega-Martínez A, Pérez-Rubio G, Ambrocio-Ortiz E, Nava-Quiroz KJ, Hernández-Zenteno RDJ, Abarca-Rojano E, Rodríguez-Llamazares S, Hernández-Pérez A, García-Gómez L, Ramírez-Venegas A, Falfán-Valencia R. The SNP rs13147758 in the HHIP Gene Is Associated With COPD Susceptibility, Serum, and Sputum Protein Levels in Smokers. Front Genet 2020; 11:882. [PMID: 33193570 PMCID: PMC7541950 DOI: 10.3389/fgene.2020.00882] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 07/17/2020] [Indexed: 12/25/2022] Open
Abstract
Background Genetic association studies have identified single nucleotide polymorphisms (SNPs) related to chronic obstructive pulmonary disease (COPD) susceptibility. The aim of this study was to identify HHIP genetic variants associated with COPD, pulmonary function, and serum and sputum HHIP protein levels in Mexican mestizo smokers. Materials and Methods Association analysis was performed by carrying out a case-control study in Mexican mestizo smokers comprised of two groups: tobacco-smoking subjects with COPD (COPD-TS, n = 222) and smokers without COPD (SWOC, n = 333). We evaluated three SNPs (rs13147758, rs1828591, and rs13118928) in the HHIP gene. Allele discrimination was accomplished by qPCR using TaqMan probes, and determination of protein levels in the serum and sputum supernatants (SS) was performed using ELISA. Results Statistically significant differences were observed in the rs13147758 GG genotype (adjusted p = 0.014, OR = 1.95) and the rs13147758-rs1828591 GA haplotype (p = 6.6E-06, OR = 2.65) in the case-control comparison. HHIP protein levels were elevated in SS samples from the COPD-TS group compared to those from the SWOC group (p = 0.03). Based on genotype analysis, HHIP protein levels were lower in the serum samples of rs13147758 GG genotype carriers in the COPD-TS group than in the serum samples of rs13147758 GG genotype carriers from the SWOC group (p < 0.05), but there were no differences in the sputum samples. Conclusion The rs13147758 GG genotype and the rs13147758-rs1828591 GA haplotype are associated with susceptibility to COPD. Furthermore, an association in protein levels was observed between the HHIP rs13147758 genotype and COPD in Mexican mestizo smokers.
Collapse
Affiliation(s)
- Alejandro Ortega-Martínez
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.,Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico
| | - Gloria Pérez-Rubio
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| | - Enrique Ambrocio-Ortiz
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| | - Karol J Nava-Quiroz
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| | - Rafael de Jesus Hernández-Zenteno
- Tobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| | - Edgar Abarca-Rojano
- Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico
| | - Sebastián Rodríguez-Llamazares
- Tobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| | - Andrea Hernández-Pérez
- Tobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| | - Leonor García-Gómez
- Tobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| | - Alejandra Ramírez-Venegas
- Tobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| | - Ramcés Falfán-Valencia
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| |
Collapse
|
6
|
Tsai CY, Chou HC, Chen CM. Perinatal nicotine exposure alters lung development and induces HMGB1-RAGE expression in neonatal mice. Birth Defects Res 2020; 113:570-578. [PMID: 33166075 DOI: 10.1002/bdr2.1840] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2020] [Revised: 10/17/2020] [Accepted: 10/31/2020] [Indexed: 12/13/2022]
Abstract
BACKGROUND Maternal nicotine exposure during gestation and lactation adversely affect lung development of their children. High-mobility group box 1 (HMGB1) is the encoded non-histone, nuclear DNA-binding protein that regulates transcription, and is involved in organization of DNA. Receptors for advanced glycation end products (RAGE) is a receptor for HMGB1 and activates nuclear factor-κB (NF-κB) signaling. Animal and human studies have found cigarette smoke exposure upregulates RAGE expression, suggesting that the HMGB1-RAGE pathway might be involved in maternal nicotine-induced lung injury. METHODS This study evaluated prenatal and perinatal nicotine effects on lung development and HMGB1 and RAGE expression in mouse offspring. Nicotine was administered to pregnant mice by subcutaneous osmotic mini-pump at a dose of 6 mg kg-1 day-1 from gestational Day 14 to birth (prenatal) or to postnatal Day 21 (perinatal). A control group received an equal volume of saline by the same route. Three study groups were obtained: prenatal normal saline (NS), prenatal nicotine, and perinatal nicotine groups. The mice were euthanized on postnatal Day 21, and the lung tissues were collected for histological and Western blot analyses. RESULTS Mice exposed to prenatal nicotine exhibited significantly higher lung mean chord length and oxidative stress marker 8-hydroxy-2'-deoxyguanosine and NF-κB expression compared to mice exposed to NS. Perinatal nicotine exposure further enhanced these harmful effects. These perinatal nicotine effects on lung development were associated with increased HMGB1 and RAGE expression. CONCLUSIONS HMGB1-RAGE pathway may be involved in the pathogenesis of altered lung development induced by perinatal nicotine exposure.
Collapse
Affiliation(s)
- Chin-Yen Tsai
- Department of Pediatrics, Yuan's General Hospital, Kaohsiung, Taiwan
| | - Hsiu-Chu Chou
- Department of Anatomy and Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Chung-Ming Chen
- Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.,Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan
| |
Collapse
|
7
|
Ortega-Martínez A, Pérez-Rubio G, Ramírez-Venegas A, Ramírez-Díaz ME, Cruz-Vicente F, Martínez-Gómez MDL, Ramos-Martínez E, Abarca-Rojano E, Falfán-Valencia R. Participation of HHIP Gene Variants in COPD Susceptibility, Lung Function, and Serum and Sputum Protein Levels in Women Exposed to Biomass-Burning Smoke. Diagnostics (Basel) 2020; 10:E734. [PMID: 32977420 PMCID: PMC7598157 DOI: 10.3390/diagnostics10100734] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Revised: 09/14/2020] [Accepted: 09/16/2020] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND A variety of organic materials (biomass) are burned for cooking and heating purposes in poorly ventilated houses; smoke from biomass combustion is considered an environmental risk factor for chronic obstructive pulmonary disease COPD. In this study, we attempted to determine the participation of single-nucleotide variants in the HHIP (hedgehog-interacting protein) gene in lung function, HHIP serum levels, and HHIP sputum supernatant levels in Mexican women with and without COPD who were exposed to biomass-burning smoke. METHODS In a case-control study (COPD-BS, n = 186, BBES, n = 557) in Mexican women, three SNPs (rs13147758, rs1828591, and rs13118928) in the HHIP gene were analyzed by qPCR; serum and supernatant sputum protein levels were determined through ELISA. RESULTS The rs13118928 GG genotype is associated with decreased risk (p = 0.021, OR = 0.51, CI95% = 0.27-0.97) and the recessive genetic model (p = 0.0023); the rs1828591-rs13118928 GG haplotype is also associated with decreased risk (p = 0.04, OR = 0.65, CI95% 0.43-0.98). By the dominant model (rs13118928), the subjects with one or two copies of the minor allele (G) exhibited higher protein levels. Additionally, two correlations with the AG genotype were identified: BBES with FEV1 (p = 0.03, r2 = 0.53) and COPD-BS with FEV1/FVC (p = 0.012, r2 = 0.54). CONCLUSIONS Single-nucleotide variants in the HHIP gene are associated with decreased COPD risk, higher HHIP serum levels, and better lung function in Mexican women exposed to biomass burning.
Collapse
Affiliation(s)
- Alejandro Ortega-Martínez
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico; (A.O.-M.); (G.P.-R.)
- Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Casco de Santo Tomas, Mexico City 11340, Mexico
| | - Gloria Pérez-Rubio
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico; (A.O.-M.); (G.P.-R.)
| | - Alejandra Ramírez-Venegas
- Tobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico;
| | - María Elena Ramírez-Díaz
- Coordinación de Vigilancia Epidemiológica, Jurisdicción 06 Sierra, Tlacolula de Matamoros Oaxaca, Servicios de Salud de Oaxaca, Oaxaca 70400, Mexico;
| | - Filiberto Cruz-Vicente
- Internal Medicine Department. Hospital Civil Aurelio Valdivieso, Servicios de Salud de Oaxaca, Oaxaca 68050, Mexico;
| | | | - Espiridión Ramos-Martínez
- Experimental Medicine Research Unit, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 06720, Mexico;
| | - Edgar Abarca-Rojano
- Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Casco de Santo Tomas, Mexico City 11340, Mexico
| | - Ramcés Falfán-Valencia
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico; (A.O.-M.); (G.P.-R.)
| |
Collapse
|
8
|
Hu L, Liu J, Zhang W, Wang T, Zhang N, Lee YH, Lu H. FUNCTIONAL METABOLOMICS DECIPHER BIOCHEMICAL FUNCTIONS AND ASSOCIATED MECHANISMS UNDERLIE SMALL-MOLECULE METABOLISM. MASS SPECTROMETRY REVIEWS 2020; 39:417-433. [PMID: 31682024 DOI: 10.1002/mas.21611] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/21/2019] [Revised: 10/08/2019] [Accepted: 10/10/2019] [Indexed: 06/10/2023]
Abstract
Metabolism is the collection of biochemical reactions enabled by chemically diverse metabolites, which facilitate different physiological processes to exchange substances and synthesize energy in diverse living organisms. Metabolomics has emerged as a cutting-edge method to qualify and quantify the metabolites in different biological matrixes, and it has the extraordinary capacity to interrogate the biological significance that underlies metabolic modification and modulation. Liquid chromatography combined with mass spectrometry (LC/MS), as a robust platform for metabolomics analysis, has increased in popularity over the past 10 years due to its excellent sensitivity, throughput, and versatility. However, metabolomics investigation currently provides us with only phenotype data without revealing the biochemical functions and associated mechanisms. This limitation indeed weakens the core value of metabolomics data in a broad spectrum of the life sciences. In recent years, the scientific community has actively explored the functional features of metabolomics and translated this cutting-edge approach to be used to solve key multifaceted questions, such as disease pathogenesis, the therapeutic discovery of drugs, nutritional issues, agricultural problems, environmental toxicology, and microbial evolution. Here, we are the first to briefly review the history and applicable progression of LC/MS-based metabolomics, with an emphasis on the applications of metabolic phenotyping. Furthermore, we specifically highlight the next era of LC/MS-based metabolomics to target functional metabolomes, through which we can answer phenotype-related questions to elucidate biochemical functions and associated mechanisms implicated in dysregulated metabolism. Finally, we propose many strategies to enhance the research capacity of functional metabolomics by enabling the combination of contemporary omics technologies and cutting-edge biochemical techniques. The main purpose of this review is to improve the understanding of LC/MS-based metabolomics, extending beyond the conventional metabolic phenotype toward biochemical functions and associated mechanisms, to enhance research capability and to enlarge the applicable scope of functional metabolomics in small-molecule metabolism in different living organisms.
Collapse
Affiliation(s)
- Longlong Hu
- Laboratory for Functional Metabolomics Science, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China
| | - Jingjing Liu
- Laboratory for Functional Metabolomics Science, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China
| | - Wenhua Zhang
- Laboratory for Functional Metabolomics Science, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China
- Department of Pharmacognosy, College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 150040, China
| | - Tianyu Wang
- Laboratory for Functional Metabolomics Science, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China
| | - Ning Zhang
- Department of Pharmacognosy, College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, 150040, China
- Department of Pharmaceutical Analysis, College of Jiamusi, Heilongjiang University of Chinese Medicine, Harbin, 121000, China
| | - Yie Hou Lee
- Translational 'Omics and Biomarkers Group, KK Research Centre, KK Women's and Children's Hospital, Singapore, 229899, Singapore
- OBGYN-Academic Clinical Program, Duke-NUS Medical School, Singapore, 169857, Singapore
| | - Haitao Lu
- Laboratory for Functional Metabolomics Science, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China
| |
Collapse
|
9
|
Belgacemi R, Luczka E, Ancel J, Diabasana Z, Perotin JM, Germain A, Lalun N, Birembaut P, Dubernard X, Mérol JC, Delepine G, Polette M, Deslée G, Dormoy V. Airway epithelial cell differentiation relies on deficient Hedgehog signalling in COPD. EBioMedicine 2020; 51:102572. [PMID: 31877414 PMCID: PMC6931110 DOI: 10.1016/j.ebiom.2019.11.033] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Revised: 10/11/2019] [Accepted: 11/20/2019] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Hedgehog (HH) pathway is constantly under scrutiny in the context of organ development. Lung morphogenesis requires HH signalling which participates thereafter to the pulmonary homeostasis by regulating epithelial cell quiescence and repair. Since epithelial remodelling is a hallmark of Chronic Obstructive Pulmonary Disease (COPD), we investigated whether the main molecular actors of HH pathway participate to airway epithelial cell differentiation and we analysed their alterations in COPD patients. METHODS Sonic HH (Shh) secretion was assessed by ELISA in airway epithelial cell (AEC) air-liquid interface culture supernatants. HH pathway activation was evaluated by RT-qPCR, western blot and immunostaining. Inhibition of HH signalling was achieved upon Shh chelation during epithelial cell differentiation. HH pathway core components localization was investigated in lung tissues from non-COPD and COPD patients. FINDINGS We demonstrate that progenitors of AEC produced Shh responsible for the activation of HH signalling during the process of differentiation. Preventing the ligand-induced HH activation led to the establishment of a remodelled epithelium with increased number of basal cells and reduced ciliogenesis. Gli2 activating transcription factor was demonstrated as a key-element in the regulation of AEC differentiation. More importantly, Gli2 and Smo were lost in AEC from COPD patients. INTERPRETATION Our data suggest that HH pathway is crucial for airway epithelial cell differentiation and highlight its role in COPD-associated epithelial remodelling.
Collapse
Affiliation(s)
- Randa Belgacemi
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France
| | - Emilie Luczka
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France
| | - Julien Ancel
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Maison Blanche, Service de pneumologie, Reims 51092, France
| | - Zania Diabasana
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France
| | - Jeanne-Marie Perotin
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Maison Blanche, Service de pneumologie, Reims 51092, France
| | - Adeline Germain
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France
| | - Nathalie Lalun
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France
| | - Philippe Birembaut
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Maison Blanche, Laboratoire de biopathologie, Reims 51092, France
| | - Xavier Dubernard
- CHU Reims, Hôpital Robert Debré, Service d'oto-rhino-laryngologie, Reims 51092, France
| | - Jean-Claude Mérol
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Robert Debré, Service d'oto-rhino-laryngologie, Reims 51092, France
| | - Gonzague Delepine
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Robert Debré, Service de chirurgie cardio-vasculaire et thoracique, Reims 51092, France
| | - Myriam Polette
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Maison Blanche, Laboratoire de biopathologie, Reims 51092, France
| | - Gaëtan Deslée
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Maison Blanche, Service de pneumologie, Reims 51092, France
| | - Valérian Dormoy
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France.
| |
Collapse
|
10
|
Musunuru K, Bernstein D, Cole FS, Khokha MK, Lee FS, Lin S, McDonald TV, Moskowitz IP, Quertermous T, Sankaran VG, Schwartz DA, Silverman EK, Zhou X, Hasan AAK, Luo XZJ. Functional Assays to Screen and Dissect Genomic Hits: Doubling Down on the National Investment in Genomic Research. CIRCULATION-GENOMIC AND PRECISION MEDICINE 2019; 11:e002178. [PMID: 29654098 DOI: 10.1161/circgen.118.002178] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The National Institutes of Health have made substantial investments in genomic studies and technologies to identify DNA sequence variants associated with human disease phenotypes. The National Heart, Lung, and Blood Institute has been at the forefront of these commitments to ascertain genetic variation associated with heart, lung, blood, and sleep diseases and related clinical traits. Genome-wide association studies, exome- and genome-sequencing studies, and exome-genotyping studies of the National Heart, Lung, and Blood Institute-funded epidemiological and clinical case-control studies are identifying large numbers of genetic variants associated with heart, lung, blood, and sleep phenotypes. However, investigators face challenges in identification of genomic variants that are functionally disruptive among the myriad of computationally implicated variants. Studies to define mechanisms of genetic disruption encoded by computationally identified genomic variants require reproducible, adaptable, and inexpensive methods to screen candidate variant and gene function. High-throughput strategies will permit a tiered variant discovery and genetic mechanism approach that begins with rapid functional screening of a large number of computationally implicated variants and genes for discovery of those that merit mechanistic investigation. As such, improved variant-to-gene and gene-to-function screens-and adequate support for such studies-are critical to accelerating the translation of genomic findings. In this White Paper, we outline the variety of novel technologies, assays, and model systems that are making such screens faster, cheaper, and more accurate, referencing published work and ongoing work supported by the National Heart, Lung, and Blood Institute's R21/R33 Functional Assays to Screen Genomic Hits program. We discuss priorities that can accelerate the impressive but incomplete progress represented by big data genomic research.
Collapse
Affiliation(s)
- Kiran Musunuru
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.).
| | - Daniel Bernstein
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - F Sessions Cole
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Mustafa K Khokha
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Frank S Lee
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Shin Lin
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Thomas V McDonald
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Ivan P Moskowitz
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Thomas Quertermous
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Vijay G Sankaran
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - David A Schwartz
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Edwin K Silverman
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Xiaobo Zhou
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Ahmed A K Hasan
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| | - Xiao-Zhong James Luo
- Cardiovascular Institute, Department of Medicine (K.M.), Department of Genetics (K.M.), and Department of Pathology and Laboratory Medicine (F.S.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Department of Pediatrics (D.B.), Cardiovascular Institute (D.B., T.Q.), and Department of Medicine (T.Q.), Stanford University, CA. Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO (F.S.C.). St. Louis Children's Hospital, MO (F.S.C.). Pediatric Genomics Discovery Program, Department of Pediatrics and Genetics, Yale University School of Medicine, New Haven, CT (M.K.K.). Division of Cardiology, Department of Medicine, University of Washington, Seattle (S.L.). Department of Cardiovascular Sciences, University of South Florida Morsani College of Medicine, Tampa, FL (T.V.M.). Department of Pediatrics (I.P.M.), Department of Pathology (I.P.M.), and Department of Human Genetics (I.P.M.), The University of Chicago, IL. Division of Hematology/ Oncology, Boston Children's Hospital, MA (V.G.S.). Department of Pediatric Oncology, Dana-Farber Cancer Institute (V.G.S.) and Channing Division of Network Medicine, Brigham and Women's Hospital (E.K.S., X.Z.), Harvard Medical School, Boston. Broad Institute of MIT and Harvard, Cambridge, MA (V.G.S.). University of Colorado, Aurora (D.A.S.). Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (A.A.K.H., X.-z.J.L.)
| |
Collapse
|
11
|
Wadhwa R, Aggarwal T, Malyla V, Kumar N, Gupta G, Chellappan DK, Dureja H, Mehta M, Satija S, Gulati M, Maurya PK, Collet T, Hansbro PM, Dua K. Identification of biomarkers and genetic approaches toward chronic obstructive pulmonary disease. J Cell Physiol 2019; 234:16703-16723. [DOI: 10.1002/jcp.28482] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 02/10/2019] [Accepted: 02/14/2019] [Indexed: 12/26/2022]
Affiliation(s)
- Ridhima Wadhwa
- Faculty of Life Sciences and Biotechnology South Asian University New Delhi India
| | - Taru Aggarwal
- Amity Institute of Biotechnology Amity University Noida Uttar Pradesh India
| | - Vamshikrishna Malyla
- Discipline of Pharmacy, Graduate School of Health University of Technology Sydney New South Wales Australia
- Centre for Inflammation Centenary Institute Sydney New South Wales Australia
| | - Nitesh Kumar
- Amity Institute for Advanced Research & Studies (M&D) Amity University Noida Uttar Pradesh India
| | - Gaurav Gupta
- School of Pharmaceutical Sciences Jaipur National University, Jagatpura Jaipur Rajasthan India
| | - Dinesh Kumar Chellappan
- Department of Life Sciences, School of Pharmacy International Medical University Bukit Jalil Kuala Lumpur Malaysia
| | - Harish Dureja
- Department of Pharmaceutical Sciences Maharishi Dayanand University Rohtak Haryana India
| | - Meenu Mehta
- School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India
| | - Saurabh Satija
- School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India
| | - Monica Gulati
- School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India
| | - Pawan Kumar Maurya
- Department of Biochemistry Central University of Haryana Mahendergarh Haryana India
| | - Trudi Collet
- Innovative Medicines Group, Institute of Health & Biomedical Innovation Queensland University of Technology Brisbane Queensland Australia
| | - Philip Michael Hansbro
- Priority Research Centre for Healthy Lungs University of Newcastle & Hunter Medical Research Institute Newcastle New South Wales Australia
- Centre for Inflammation Centenary Institute Sydney New South Wales Australia
- School of Life Sciences University of Technology Sydney Sydney New South Wales Australia
| | - Kamal Dua
- Discipline of Pharmacy, Graduate School of Health University of Technology Sydney New South Wales Australia
- Priority Research Centre for Healthy Lungs University of Newcastle & Hunter Medical Research Institute Newcastle New South Wales Australia
- Centre for Inflammation Centenary Institute Sydney New South Wales Australia
| |
Collapse
|
12
|
Huang Q, Hu D, Wang X, Chen Y, Wu Y, Pan L, Li H, Zhang J, Deng F, Guo X, Shen H. The modification of indoor PM 2.5 exposure to chronic obstructive pulmonary disease in Chinese elderly people: A meet-in-metabolite analysis. ENVIRONMENT INTERNATIONAL 2018; 121:1243-1252. [PMID: 30389378 DOI: 10.1016/j.envint.2018.10.046] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2018] [Revised: 10/22/2018] [Accepted: 10/22/2018] [Indexed: 06/08/2023]
Abstract
BACKGROUND Exposure to airborne fine particulate matter (PM2.5) has been associated with a variety of adverse health outcomes including chronic obstructive pulmonary disease (COPD). However, the linkages between PM2.5 exposure, PM2.5-related biomarkers, COPD-related biomarkers and COPD remain poorly elucidated. OBJECTIVES To investigate the linkages between PM2.5 exposure and COPD outcome by using the meet-in-middle strategy based on urinary metabolic biomarkers. METHODS A cross-sectional study was designed to illustrate the mentioned quadripartite linkages. Indoor PM2.5 and its element components were assessed in 41 Chinese elderly participants including COPD patients and their healthy spouses. Metabolic biomarkers involved in PM2.5 exposure and COPD were identified by using urinary metabolomics. The associations between PM2.5- and COPD-related biomarkers were investigated by statistics and metabolic pathway analysis. RESULTS Seven metabolites were screened and identified with significant correlations to PM2.5 exposure, which were majorly involved in purine and amino acid metabolism as well as glycolysis. Ten COPD-related metabolic biomarkers were identified, which suggested that amino acid metabolism, lipid and fatty acid metabolism, and glucose metabolism were disturbed in the patients. Also, PM2.5 and its many elemental components were significantly associated with COPD-related biomarkers. We observed that the two kinds of biomarkers (PM2.5- and COPD-related) integrated in a locally connected network and the alterations of these metabolic biomarkers can biologically link PM2.5 exposure to COPD outcome. CONCLUSIONS Our study indicated the modification of PM2.5 to COPD via both modes of action of lowering participants' antioxidation capacity and decreasing their lung energy generation; this information would be valuable for the prevention strategy of COPD.
Collapse
Affiliation(s)
- Qingyu Huang
- Key Laboratory of Urban Environment and Health, Institute of Urban Environment, Chinese Academy of Sciences, Xiamen 361021, China
| | - Dayu Hu
- Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Xiaofei Wang
- Key Laboratory of Urban Environment and Health, Institute of Urban Environment, Chinese Academy of Sciences, Xiamen 361021, China
| | - Yahong Chen
- Respiratory Department, Peking University Third Hospital, No. 49 North Garden Road, Beijing 100191, China
| | - Yan Wu
- Key Laboratory of Urban Environment and Health, Institute of Urban Environment, Chinese Academy of Sciences, Xiamen 361021, China
| | - Lu Pan
- Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Hongyu Li
- Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Jie Zhang
- Key Laboratory of Urban Environment and Health, Institute of Urban Environment, Chinese Academy of Sciences, Xiamen 361021, China
| | - Furong Deng
- Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, No. 38 Xueyuan Road, Beijing 100191, China.
| | - Xinbiao Guo
- Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Heqing Shen
- Key Laboratory of Urban Environment and Health, Institute of Urban Environment, Chinese Academy of Sciences, Xiamen 361021, China.
| |
Collapse
|
13
|
Xu J, Shang Y, Cai F, Zhang S, Xiao Z, Wang H, Fan Y, Li T, Sheng S, Fu Y, Chi F, Zhou C. Correlation between lung cancer and the HHIP polymorphisms of chronic obstructive pulmonary disease (COPD) in the Chinese Han population. Genes Immun 2018; 20:273-280. [PMID: 29915314 DOI: 10.1038/s41435-018-0033-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Revised: 04/10/2018] [Accepted: 04/17/2018] [Indexed: 11/09/2022]
Abstract
To further investigate the relationship between lung cancer and hedgehog interacting protein (HHIP) polymorphisms of chronic obstructive pulmonary disease (COPD) patients, we conducted a case-control study in a Chinese Han population. Six HHIP SNPs with minor allele frequencies >5% (rs1489758, rs1489759, rs10519717, rs13131837, rs1492820, and rs7689420) were analyzed in 1,017 COPD patients (767 males and 246 females) and 430 non-COPD patients. Using logistic regression analysis, we found that rs7689420 was significantly associated with lung cancer in COPD patients in the Chinese Han population (P < 0.001). The recessive allele of rs7689420 was associated with the occurrence of lung cancer in all COPD patients (odds ratios [OR] of 0.609 and 0.424 for the CT and TT genotypes, respectively) as well as in serious COPD patients (OR of 0.403 and 0.305 for CT and TT, respectively). Additionally, rs1489759 and rs3131837 were associated with lung cancer in various genetic models. rs1489758, rs1489759, and rs10519717 were also associated with lung cancer in serious COPD patients. However, none of the SNPs were significantly associated with lung cancer in mild COPD patients or healthy subjects. Therefore, the HHIP SNPs of COPD patients likely play a role in lung cancer pathology in the Chinese Han population.
Collapse
Affiliation(s)
- Jing Xu
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China.
| | - Yan Shang
- Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, 200433, Shanghai, China
| | - Feng Cai
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China
| | - Shu Zhang
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China
| | - Zhong Xiao
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China
| | - Haitao Wang
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China
| | - Yanhong Fan
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China
| | - Ting Li
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China
| | - Shuhong Sheng
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China
| | - Youhui Fu
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China
| | - Feng Chi
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China
| | - Chen Zhou
- Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, 200137, Shanghai, China
| |
Collapse
|